Antibody screening for tumor and immune hotspot targets: The frontier of new methods and technologies

Advancements in tumor immunotherapy highlight the significant potential of antibody drugs, a key category of biological agents, for treating cancer and autoimmune diseases. This paper begins by defining and classifying key targets in tumor immunity, as well as discussing their structural and functional characteristics. Subsequently, it elaborates on innovative technologies for antibody drug screening, which, when integrated with contemporary molecular biology, biotechnology, and computational biology, have substantially enhanced the efficiency and accuracy of target identification and antibody drug screening processes. Despite the promising prospects of tumor immunotherapy, certain limitations persist in its practical implementation. In conclusion, this paper offers a comprehensive examination of the cutting-edge developments in tumor immunotherapy, focusing on the aspects of tumor immunotherapy itself, critical targets for immunotherapy, and novel technologies and methodologies for antibody screening. This analysis is crucial for advancing the field of tumor immunotherapy and for enhancing both therapeutic efficacy and safety. Furthermore, research and development (R&D) of antibody drugs in other domains, such as autoimmune and inflammatory diseases, can benefit from it.